Background and Purpose: Stroke is the major cause of vascular behavior and cognitive disorders worldwide. In developing countries, there is a dearth of information regarding the public health magnitude of stroke. The aim of the Fogarty-Mexico cohort was to assess the prevalence of vascular behavioral and cognitive disorders, ranging from mild vascular cognitive impairment (VCI) to vascular dementia (VaD), in a cohort of acute first-ever symptomatic stroke patients in Mexico. Methods: A total of 165 consecutive, first-ever stroke patients admitted to the National Institute of Neurology and Neurosurgery in Mexico City, were included in the cohort. Patients were eligible if they had an ischemic stroke, primary intracerebral hemorrhage, or cerebral venous thrombosis (CVT). Stroke diagnosis required the presence of an acute focal deficit lasting more than 24 h, confirmed by a corresponding lesion on CT/MRI. Stroke severity was established with the NIH Stroke Scale. The pre-stroke functional status was determined by the IQCODE. Three months after the occurrence of stroke, 110 survivor patients returned for follow-up and were able to undergo functional outcome (modified Rankin scale, Barthel index), along with neurological, psychiatric, neuropsychological, laboratory, and imaging assessments. We compared depression, demographic, and clinical and imaging features between patients with and without dementia, and between patients with VCI and those with intact cognition. Results: Of the 110 patients (62% men, mean age 56 ± 17.8, education 7.7 ± 5.2 years) 93 (84%) had ischemic strokes, 14 (13%) intracerebral hemorrhage, and 3 (3%) CVT. The main risk factors were hypertension (50%), smoking (40%), hypercholesterolemia (29%), hyperhomocysteinemia (24%), and diabetes (22%). Clinical and neuropsychological evaluations demonstrated post-stroke depression in 56%, VCI in 41%, and VaD in 12%; 17% of the latter had pre-stroke functional impairment (IQCODE >3.5). Cognitive deficits included executive function in 69%, verbal memory in 49%, language in 38%, perception in 36%, and attention in 38%. Executive dysfunction occurred in 36% of non-demented subjects, 65% of them with mild-moderate deficits in daily living activities. Female gender (p ≤ 0.054), older age (mean age 65.6 years vs. 49.3, p < 0.001), diabetes (p ≤ 0.004), illiteracy and lower education (p ≤ 0.001), and PSD (p = 0.03) were significantly higher in VCI-VaD compared with cognitively intact post-stroke subjects. We could not demonstrate an association with lesion site and distribution of the cognitive deficits. Conclusions: The Fogarty-Mexico cohort recruited relatively young acute stroke patients, compared with other Mexican stroke cohorts. PSD and VCI occurred frequently but prevalence of VaD (12%) was lower than expected. A high prevalence of treatable stroke risk factors suggests that preventive interventions are advisable.

Keywords:
Mexico, Post-stroke depression, Stroke, Vascular cognitive disorders, Vascular cognitive impairment, Vascular dementia
1.
WHO: World Health Organization, World Health Statistics. Geneva, Switzerland, 2013.
2.
Román G: Vascular dementia may be the most common form of dementia in the elderly. J Neurol Sci 2002;203-204:7-10.
3.
Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al: Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013;136:2697-2706.
4.
Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, et al: Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672-2713.
5.
Sachdev P, Kalaria R, O'Brien J, Skoog I, Alladi S, Black SE, et al: Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 2014;28:206-218.
6.
Miralbell J, López-Cancio E, López-Oloriz J, Arenillas JF, Barrios M, Soriano-Raya JJ, et al: Cognitive patterns in relation to biomarkers of cerebrovascular disease and vascular risk factors. Cerebrovasc Dis 2013;36:98-105.
7.
O'Brien JT, Erkinjuntti T, Reisberg B, Román G, Sawada T, Pantoni L, et al: Vascular cognitive impairment. Lancet Neurol 2003;2:89-98.
8.
Desmond DW, Moroney JT, Paik MC, et al: Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000;54:1124-1131.
9.
Hackett ML, Yapa C, Parag V, Anderson CS: Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330-1340.
10.
Ayerbe L, Ayis S, Wolfe CD, Rudd AG: Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry 2013;202:14-21.
11.
Cantú-Brito C, Majersik JJ, Sánchez BN, Ruano A, Quiñones G, Arzola J, et al: Hospitalized stroke surveillance in the community of Durango, Mexico: the brain attack surveillance in Durango Study. Stroke 2010;41:878-884.
12.
Kasner SE: Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-612.
13.
Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015-1022.
14.
Adams HP Jr, Bendixen BH, Kappelle LJ, et al: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
15.
Jurado S, Villegas M: La estandarización del Inventario de Depresión de Beck para los residentes de la Ciudad de México. Salud Mental 1998;21:26-31.
16.
Marin RS: Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3:243-254.
17.
Teng EL: Manual of the Cognitive Abilities Screening Instrument (CASI). Versions E-1.0. Los Angeles, University of Southern California School of Medicine, 1999.
18.
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
19.
Paolo AM, et al: California Verbal Learning Test: normative data for the elderly. J Clin Exp Neuropsychol 1997;19:220-234.
20.
Wechsler D, Sánchez P: Escala de Wechsler de Inteligencia para adultos. WAIS-III, ed 2. Mexico City, Manual Moderno, 2003.
21.
Lezak M, Howieson D, Loring D: Neuropsychological Assessment, ed 4. New York, Oxford University Press, 2004.
22.
Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992;40:1221-1226.
23.
Royall DR, Cordes JA, Polk M: CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry 1998;64:588-594.
24.
Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I: Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000;54:447-451.
25.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DC, American Psychiatric Association, 1994.
26.
Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, García JH, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
27.
Serrano S, Domingo J, Rodríguez-Garcia E, Castro MD, Del Ser T: Frequency of cognitive impairment without dementia in patients with stroke: a two-year follow-up study. Stroke 2007;38:105-110.
28.
Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F: Poststroke dementia. Lancet Neurol 2005;4:752-759.
29.
Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V: The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997;337:1667-1674.
30.
Arauz A, Hoyos L, Espinoza C, Cantú C, Barinagarrementeria F, Román G: Dissection of cervical arteries: long-term follow-up study of 130 consecutive cases. Cerebrovasc Dis 2006;22:150-154.
31.
Arauz A, Márquez JM, Artigas C, Balderrama J, Orrego H: Recanalization of vertebral artery dissection. Stroke 2010;41:717-721.
32.
Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke 1998;29:75-81.
33.
Hénon H, Pasquier F, Durieu I: Preexisting dementia in stroke patients. Baseline frequency, associated factors and outcome. Stroke 1997;28:2429-2436.
34.
Román GC, Nash DT, Fillit H: Translating current knowledge into dementia prevention. Alzheimer Dis Assoc Disord 2012;26:295-299.
35.
Willis KJ, Hakim AM: Stroke prevention and cognitive reserve: emerging approaches to modifying risk and delaying onset of dementia. Front Neurol 2013;4:13.
36.
Verdelho A, Hénon H, Lebert F, Pasquier F, Leys D: Depressive symptoms after stroke and relationship with dementia: a three-year follow-up study. Neurology 2004;62:905-911.
37.
Paolucci S: Epidemiology and treatment of post-stroke depression. Neuropsychiatr Dis Treat 2008;4:145-154.
38.
Robinson RG, Spalletta G: Poststroke depression: a review. Can J Psychiatry 2010;55:341-349.
39.
Sibolt G, Curtze S, Melkas S, Pohjasvaara T, Kaste M, Karhunen PJ, Oksala NK, Vataja R, Erkinjuntti T: Post-stroke depression and depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke. Cerebrovasc Dis 2013;36:336-343.
40.
Vataja R, Pohjasvaara T, Mäntylä R, et al: Depression-executive dysfunction syndrome in stroke patients. Am J Geriatr Psychiatry 2005;13:99-107.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.